Erika Lietzan is an Associate Professor of Law at the University of Missouri School of Law. She researches and writes primarily in the areas of drug and device regulation, intellectual property, and administrative law. Some of her more recent scholarship has focused on the possibility of reverse payment patent settlements between biologic innovators and biosimilar sponsors, data exclusivity for drugs and biologics, mandatory release of clinical data in drug applications, generic drug exclusivity, preemption of failure to warn suits against generic and innovative drug companies, and conflicts of interest on FDA advisory committees. Also, she has recently written book chapters on the regulation of biosimilar biological products and the regulation of drug and device clinical trials. She has also written more than a dozen shorter pieces for a variety of other publications, including two empirical pieces on judicial review of FDA action.
Professor Lietzan is an elected member of the American Law Institute. She serves in the leadership of the Science and Technology Section of the American Bar Association and in the leadership of the Food and Drug Law Institute, and she is an active member of the American Health Lawyers Association, the American Intellectual Property Law Association, and the American Society of Law, Medicine, and Ethics.
Professor Lietzan received a bachelor’s degree from the University of North Carolina, where she graduated with honors in history. She received a master’s degree in intellectual history from UCLA and a law degree with high honors from Duke Law School. After law school, she clerked on the United States Court of Appeals for the Eleventh Circuit and then joined Covington & Burling LLP in Washington, DC, where she made partner in the firm’s Food and Drug group. She also briefly worked in-house as Assistant General Counsel of the Pharmaceutical Research and Manufacturers of America.
Professor Lietzan teaches drug and device regulation, intellectual property, and administrative law.